A multi-center, open-label extension study to examine the safety and tolerability of ACP-103 in the treatment of psychosis in Parkinson's disease
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Acadia Pharmaceuticals
- 08 Jun 2018 Status changed from active, no longer recruiting to completed.
- 18 Apr 2017 Planned End Date changed from 1 Dec 2015 to 1 Jan 2018.
- 17 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History